Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 39Terminated 19Unknown 13Recruiting 6Active not recruiting 3Withdrawn 2Not yet recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

CNS 78Sarcoma 16Gastrointestinal 8Dermatologic 6Tumor-Agnostic 4NET 4Lymphoid 4Endocrine 4Thoracic 3Other solid neoplasm 3Genitourinary 3Gynecologic 2Breast 1

Conditions

Melanoma 4Melanoma, Cutaneous Malignant 1Brain Neoplasms 1Advanced Melanoma 1

Interventions

pembrolizumab 65Nivolumab 59Ipilimumab 33Cyclophosphamide 23Specimen Handling 16Magnetic Resonance Spectroscopy 15Biopsy 15relatlimab 13fludarabine 13cemiplimab 13Opdualag 12Blood Specimen Collection 11binimetinib 10aldesleukin 9Radiosurgery 9Interleukin-2 9encorafenib 8atezolizumab 7Immunotherapy 7tebentafusp 6mogamulizumab 6fludarabine phosphate 6Temozolomide 6Surgical Procedures, Operative 6Paclitaxel 6Immunoglobulin G 6CTLA-4 Antigen 6Aminolevulinic Acid 6Radiotherapy 5Disulfides 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Temozolomide × Dermatologic × Clear all
NCT07310784 2026-05-12

A Phase II Trial of LM103 in Advanced Melanoma

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase 2 Recruiting
92 enrolled
Dermatologic

Advanced Melanoma

NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Linnaeus Therapeutics, Inc.

Phase 2/3 Recruiting
135 enrolled
Dermatologic

Melanoma

NCT06743126 2026-04-21

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting
360 enrolled
Dermatologic

Melanoma, Cutaneous Malignant

NCT05588453 2026-01-12

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
30 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT06703398 2025-12-23

MIZAR-003

Shanghai Juncell Therapeutics

Phase 2 Recruiting
98 enrolled
Dermatologic

Melanoma

NCT05512481 2025-03-03

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Peking University Cancer Hospital & Institute

Phase 2 Recruiting
60 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡